Cervical cancer (CC) is the fourth most common cause of women death. The papillomavirus (HPV) persistent infection is the lead- ing cause for the development of CC that progresses through multistep transformation. Drug resistance and relapse are fre- quently observed in CC after conventional chemotherapy and radiotherapy. Therefore, there is a need to find new drugs against CC. Dimethyl fumarate (DMF) is an FDA-approved anti-inflam- matory drug and emerging studies suggest that DMF also exert an anti-tumor activity in some cancers. We were interested to fer- roptosis, a type of cell death caused by iron-dependent lipid per- oxidation. Using cell viability and colony assay, we tested the effectiveness of DMF alone in comparison to other well-known inducers of ferroptosis in SiHa and C4I cells. We performed fer- roptosis related-genes expression analysis, lipid peroxidation and malondialdehyde assays demonstrating that DMF induces ferrop- tosis in a concentration-dependent manner in both cell lines. Next, we investigated if the combination of DMF with sub-cyto- toxic ferroptotic-drugs was able to ameliorate ferroptosis. We found that co-treatments of DMF/sulfasalazine (SAS) were asso- ciated with enhanced cell death. To elucidate molecular mecha- nisms underlying these effects we analyzed the NRF2 antioxidant pathway. Real-time PCR and western blot assays showed an induction of NRF2 protein and NRF2-dependent genes, such as SLC7A11 involved in GSH synthesis. In contrast with the observed SLC7A11 increase, we detected a strong reduction of glutathione (GSH) under DMF/SAS treatments. These results indicate that SAS cooperates in GSH depletion favoring ferrop- tosis. Since DMF has been found to influence NF-kB, STAT3 signaling we also tested IL-6 levels, a NF-kB target, and phos- phorylation of STAT3 in DMF/SAS treatments. Our results demonstrate that both these pathways are reduced in presence of SAS, implicating that DMF/SAS exhibited a strong killing-effect than either DMF or SAS alone.
Redox modulation and induction of ferroptosis by dimethyl fumarate in cervical carcinoma / Punziano, C.; Minopoli, G.; Tornesello, M. L.; Faraonio, R.. - In: FEBS OPENBIO. - ISSN 2211-5463. - 14:(2024), pp. 333-333. [10.1002/2211-5463.13837]
Redox modulation and induction of ferroptosis by dimethyl fumarate in cervical carcinoma
C. PunzianoPrimo
;R. FaraonioUltimo
2024
Abstract
Cervical cancer (CC) is the fourth most common cause of women death. The papillomavirus (HPV) persistent infection is the lead- ing cause for the development of CC that progresses through multistep transformation. Drug resistance and relapse are fre- quently observed in CC after conventional chemotherapy and radiotherapy. Therefore, there is a need to find new drugs against CC. Dimethyl fumarate (DMF) is an FDA-approved anti-inflam- matory drug and emerging studies suggest that DMF also exert an anti-tumor activity in some cancers. We were interested to fer- roptosis, a type of cell death caused by iron-dependent lipid per- oxidation. Using cell viability and colony assay, we tested the effectiveness of DMF alone in comparison to other well-known inducers of ferroptosis in SiHa and C4I cells. We performed fer- roptosis related-genes expression analysis, lipid peroxidation and malondialdehyde assays demonstrating that DMF induces ferrop- tosis in a concentration-dependent manner in both cell lines. Next, we investigated if the combination of DMF with sub-cyto- toxic ferroptotic-drugs was able to ameliorate ferroptosis. We found that co-treatments of DMF/sulfasalazine (SAS) were asso- ciated with enhanced cell death. To elucidate molecular mecha- nisms underlying these effects we analyzed the NRF2 antioxidant pathway. Real-time PCR and western blot assays showed an induction of NRF2 protein and NRF2-dependent genes, such as SLC7A11 involved in GSH synthesis. In contrast with the observed SLC7A11 increase, we detected a strong reduction of glutathione (GSH) under DMF/SAS treatments. These results indicate that SAS cooperates in GSH depletion favoring ferrop- tosis. Since DMF has been found to influence NF-kB, STAT3 signaling we also tested IL-6 levels, a NF-kB target, and phos- phorylation of STAT3 in DMF/SAS treatments. Our results demonstrate that both these pathways are reduced in presence of SAS, implicating that DMF/SAS exhibited a strong killing-effect than either DMF or SAS alone.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.